News from eisai inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 04, 2015, 19:01 ET

Un estudio fase III del agente antitumoral Halaven® (eribulina) en sarcoma de tejidos blandos demuestra un incremento de la supervivencia global como criterio de valoración principal

SOLO PARA LOS MEDIOS DE LA REGIÓN EMEA: NO PARA LOS MEDIOS SUIZOS/ESTADOUNIDENSES  Eisai demuestra su compromiso con los tipos de...

Mar 04, 2015, 19:01 ET
Mar 04, 2015, 19:01 ET

Uno studio di fase III sull'agente antitumorale Halaven® (eribulina) nel sarcoma dei tessuti molli dimostra un beneficio nell'endpoint primario in termini di sopravvivenza complessiva

DESTINATO ESCLUSIVAMENTE ALLA STAMPA DELL'AREA EMEA: NON DESTINATO AI GIORNALISTI DI SVIZZERA/STATI UNITI  Eisai conferma il proprio impegno...

Mar 04, 2015, 19:01 ET

Phase-III-Studie des Krebsmedikaments Halaven®(Eribulin) bei Weichteilsarkomen zeigt positive Wirkung auf den primären Endpunkt "Gesamtüberleben"

PRESSEMITTEILUNG NUR FÜR EU-MEDIEN: NICHT FÜR JOURNALISTEN AUS DER SCHWEIZ/DEN USA  Eisai engagiert sich im Bereich der seltenen...

Feb 27, 2015, 08:05 ET
Eisai logo.

LENVIMA™ (lenvatinib) Now Available Through Two Specialty Pharmacies, Accredo and Biologics, Inc.

 Eisai Inc. announced today that LENVIMA™ (lenvatinib), a receptor tyrosine kinase inhibitor, is now available through two specialty...

Feb 25, 2015, 07:55 ET

Topline Results of Phase 3 Trial Show Eribulin Mesylate Injection Meets Primary Endpoint of Overall Survival in Advanced Soft Tissue Sarcoma

 Eisai Inc. today announced that eribulin met the primary endpoint in its Phase 3 trial (Study 309), demonstrating a statistically significant...

Feb 19, 2015, 07:55 ET

Eisai Launches BELVIQ® VOICES™, an Online Community of Personal Weight Loss Stories, Featuring Real Life Experiences with BELVIQ® (lorcaserin HCl) CIV

 Eisai Inc. today announced the launch of BELVIQ VOICES, an online community featuring real life weight loss journeys of patients living with...

Feb 17, 2015, 19:01 ET

ZONEGRAN® (ZONISAMIDE), traitement de l'épilepsie des laboratoires EISAI, autorisé en France chez l'enfant et l'adolescent

COMMUNIQUÉ DE PRESSE DESTINÉ AUX MÉDIAS EUROPÉENS UNIQUEMENT  La Commission de la Transparence de la Haute Autorité...

Feb 13, 2015, 19:39 ET
Feb 13, 2015, 15:55 ET

FDA Approves Eisai's LENVIMA™ (lenvatinib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer

 Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the company's receptor tyrosine kinase inhibitor...

Feb 13, 2015, 11:15 ET
Eisai logo

Eisai Announces FDA Approval of BANZEL® (rufinamide) for Adjunctive Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Pediatric Patients Ages 1-4

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for...

Feb 13, 2015, 09:57 ET
Feb 12, 2015, 19:01 ET
Feb 12, 2015, 07:55 ET

Pivotal Phase 3 Trial of Investigational Agent Lenvatinib in Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer Published in New England Journal of Medicine

 Results from the pivotal Phase 3 SELECT (Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid) trial evaluating the use of...

Jan 22, 2015, 19:01 ET

Gemeinsamer Bundesausschuss (G-BA) bestätigt beträchtlichen Zusatznutzen von Halaven® (Eribulin)

Die Entscheidung des Gemeinsamen Bundesausschusses erkennt den therapeutischen Bedarf von Frauen mit schwer behandelbarem Brustkrebs in...

Jan 20, 2015, 07:55 ET
The Savings Card for BELVIQ(R) can be obtained at physician offices & pharmacies or via www.BELVIQ.com/registration/

Eisai Launches New Savings Card to Increase Access and Affordability of BELVIQ® (lorcaserin HCl) CIV

Eisai Inc. today announced the launch of a new savings card for BELVIQ® (lorcaserin HCl) CIV, the most prescribed branded FDA-approved...

Dec 10, 2014, 19:01 ET

Eisai's innovatives Individualimport-Programm für den ersten Vertreter einer neuen Wirkstoffklasse Fycompa® (Perampanel) wird trotz verheerender Entscheidung des G-BA fortgesetzt

- PRESSEMITTEILUNG NUR FÜR EU-MEDIEN: NICHT FÜR JOURNALISTEN AUS DER SCHWEIZ/DEN USA - Eisai bekräftigte heute seine Zusage...

Dec 09, 2014, 09:01 ET

Halaven® (eribulina) en combinación con capecitabina proporciona un beneficio clínico en mujeres con cáncer de mama metastásico

COMUNICADO DE PRENSA SOLO PARA MEDIOS DE LA UE: NO PARA PERIODISTAS SUIZOS NI ESTADOUNIDENSES  Un segundo estudio en fase II presentado en...